To amend the Patient Protection and Affordable Care Act to provide that qualified health plans are not required to use a provider network.
Summary
HR9107, a bill to remove the provider network requirement for ACA qualified health plans, was introduced and referred to committee on June 2, 2026. At this early procedural stage, the bill has no near-term market impact. The primary affected sector is healthcare, with potential implications for insurers like UnitedHealth Group, but the legislative path is long and uncertain.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9107 is in the earliest legislative stage with no committee action yet
- 2.The bill authorizes no funding and provides no direct financial incentives
- 3.Impact on insurers like UNH is minimal and uncertain at this point
Market Implications
No immediate market implications. The bill is too early-stage and narrow to move any sector or stock. Investors should monitor for committee hearings or markup as the next meaningful signal.
Full Analysis
On June 2, 2026, Representative Rulli (R-OH) introduced HR9107 in the 119th Congress. The bill proposes amending the Patient Protection and Affordable Care Act to eliminate the requirement that qualified health plans use a provider network. It has been referred to the House Committee on Energy and Commerce, the first step in the legislative process. The bill has three cosponsors and no committee markup or hearings scheduled. As an early-stage authorization bill, it does not appropriate any funds. The mechanism is regulatory relief for insurers, allowing them to offer plans without network restrictions. This could reduce administrative costs associated with network contracting and compliance, but may also increase adverse selection risk if healthier individuals choose non-network plans. The primary beneficiaries would be health insurers offering ACA exchange plans, with UnitedHealth Group being the largest publicly traded player. However, UNH's $371.6B revenue dwarfs any potential impact from this narrow regulatory change. No real market data is provided for stock prices, so no price trend analysis is possible. The legislative path requires committee consideration, House floor vote, Senate passage, and presidential action. Given the current partisan environment and the bill's early stage, passage probability is low in the near term.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.